Why Altimmune, Inc.’s (ALT) Stock Is Down 5.34%
As of Wednesday, October 14, Altimmune, Inc.’s ALT share price has dipped by 5.34%, which has investors questioning if this is right time to buy.Rosalio Madrigal
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.
Commentary & Analysis
Why Altimmune, Inc.’s (ALT) Stock Is Down 5.02%
As of Thursday, September 24, Altimmune, Inc.’s ALT share price has dipped by 5.02%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Altimmune, Inc.’s (ALT) Stock Is Down 5.09%
As of Wednesday, September 23, Altimmune, Inc.’s ALT share price has dipped by 5.09%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Altimmune, Inc.’s (ALT) Stock Is Up 6.96%
As of Wednesday, September 02, Altimmune, Inc.’s ALT share price has surged by 6.96%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Altimmune, Inc.’s (ALT) Stock Is Down 5.09%
As of Friday, August 28, Altimmune, Inc.’s ALT share price has dipped by 5.09%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | ALT | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $447.4 | $228.4 | 37% |
|
| Shares Out (Mil) | 185.4 | 53.9 | 74% |
|
| Institutional Ownership | 99.2% | 92.9% | 86% |
|
| Float (Mil) | 164.3 | 41.7 | 70% |
|
| Beta | 0.18 | 0.95 | 12% |
|
| Avg Daily Volume (000s) | 3,472 | 582 | 89% |
|
| Price Change (52-week) |
(40.0%) | 47.6% | 24% |
|
| Growth | ALT | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (12.4%) | (10.1%) | 27% |
|
| EPS (5yr) | 12.2% | 15.8% | 51 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (54.6%) | (15.7%) | 6% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 6 | |
| Current EPS | ($0.137) | ($0.588) | ($0.668) | |
| Month Ago EPS | ($0.137) | ($0.588) | ($0.668) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.167) | ($0.709) | ($0.859) | |
| Year/Year Chg | 11.4% | (41.2%) | (23.5%) | |
| Financials | ALT | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($92) | ($44) | 12% |
|
| EPS (TTM) | ($0.726) | ($1.500) | 24% |
|
| Operating Cash Flow (TTM) (Mil) | ($77) | ($33) | 7% |
|
| Net Cash Flow (TTM) (Mil) | ($120) | $2 | 13% |
|
| Long-Term Debt (Q1) (Mil) | $36 | $4 | 36% |
|
| Enterprise Value (Q1) (Mil) | $342 | $177 | 31% |
|
| Valuation | ALT | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.94 | 2.19 | 23% |
|
| P/E | na | 19.9 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | ALT | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (73.7%) | na |
|
| ROA | (25.6%) | (47.1%) | 18% |
|
| ROE | (28.9%) | (54.1%) | 20% |
|
| Liabilities to Assets | 10.1% | 29.1% | 6% |
|
| F-Score | 3 | 2 | 18% |
|
Altimmune, Inc. did not pass any screens on 10/20/2026.
